[Bisphosphonates in oncology]

Orthopade. 2007 Feb;36(2):131-5. doi: 10.1007/s00132-007-1051-1.
[Article in German]

Abstract

Since bone metastases occur as a result of hematogenous spreading of tumor cells, therapy with curative intent is no longer feasible and palliative options for treating and preventing skeletal events are essential. Today, bisphosphonates are established in the systemic treatment of bone metastases. This report provides an overview of molecular mechanisms of action and clinical data of bisphosphonates in patients with skeletal metastases of breast and prostate cancer as the most common solid tumors which spread to the bone.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Administration, Oral
  • Bone Density Conservation Agents / adverse effects
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / psychology
  • Bone Neoplasms / secondary*
  • Breast Neoplasms / drug therapy
  • Diphosphonates / adverse effects
  • Diphosphonates / therapeutic use*
  • Female
  • Fractures, Spontaneous / prevention & control*
  • Fractures, Spontaneous / psychology
  • Humans
  • Infusions, Intravenous
  • Male
  • Palliative Care
  • Prostatic Neoplasms / drug therapy
  • Quality of Life / psychology
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Diphosphonates